GlaxoSmithKline PLC Stock Options Expiring on 19th of July
| GSK Stock | USD 41.06 0.23 0.56% |
GlaxoSmithKline PLC's latest option contracts expiring on 2024-07-19 are carrying combined implied volatility of 20.1 with a put-to-call open interest ratio of 0.91 over 42 outstanding agreements suggesting investors are buying slightly more calls than puts on contracts expiring on 2024-07-19. The current put volume is at 93.0, with calls trading at the volume of 136. This yields a 0.68 put-to-call volume ratio.
Open Interest Against 2024-07-19 Option Contracts
2024-07-19
The chart above shows GlaxoSmithKline PLC's distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. GlaxoSmithKline PLC's open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for GlaxoSmithKline PLC's option, there is no secondary market available for investors to trade.
GlaxoSmithKline PLC Maximum Pain Price across 2024-07-19 Option Contracts
Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of particular securities such as GlaxoSmithKline PLC close to expiration to expire worthless. According to most research, approximately 10% to 15% of all stock options are exercised, while about 35% expire worthlessly, with roughly 50% traded out before the expiration date. So, Max pain occurs when market makers reach a net positive position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthless.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Please note that buying 'in-the-money' options on GlaxoSmithKline PLC lessens the impact of time decay, as they carry both intrinsic and time value. So, even if GlaxoSmithKline PLC's value remains static through the expiration date, the investor can sell to close an 'in-the-money' option to avoid a potential loss. However, in-the-money GlaxoSmithKline PLC contracts are usually more expensive to enter than their out-of-the-money counterparts. So keep in mind that while the payoffs on an in-the-money trade can be high, the investors could ultimately experience a more consequential loss if GlaxoSmithKline Stock moves the wrong way.
At this time, GlaxoSmithKline PLC's Total Stockholder Equity is quite stable compared to the past year. Common Stock Total Equity is expected to rise to about 1.6 B this year, although the value of Other Stockholder Equity will most likely fall to about 2.9 B. GlaxoSmithKline PLC ADR In The Money Call Balance
When GlaxoSmithKline PLC's strike price is surpassing the current stock price, the option contract against GlaxoSmithKline PLC ADR stock is said to be in the money. When it comes to buying GlaxoSmithKline PLC's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on GlaxoSmithKline PLC ADR are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
GlaxoSmithKline Current Options Market Mood
GlaxoSmithKline PLC's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps GlaxoSmithKline Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Most options investors, including buyers and sellers of GlaxoSmithKline PLC's calls and puts, are not very successful. It is estimated that an average options trader loses somewhere between 80% to 90% of the time. GlaxoSmithKline PLC's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction. Using current GlaxoSmithKline PLC's option volume and open interest to make an investment decision is considered a contrarian-sentiment measure that can be utilized in many timing strategies in both derivative and spot marketplace.
Rule 16 of the current GlaxoSmithKline contract
Base on the Rule 16, the options market is currently suggesting that GlaxoSmithKline PLC ADR will have an average daily up or down price movement of about 1.26% per day over the life of the 2024-07-19 option contract. With GlaxoSmithKline PLC trading at USD 41.06, that is roughly USD 0.52. If you think that the market is fully incorporating GlaxoSmithKline PLC's daily price movement you should consider buying GlaxoSmithKline PLC ADR options at the current volatility level of 20.1%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
GlaxoSmithKline |
GlaxoSmithKline PLC Option Chain
When GlaxoSmithKline PLC's strike price is surpassing the current stock price, the option contract against GlaxoSmithKline PLC ADR stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
2024-06-142024-06-212024-06-282024-07-052024-07-122024-07-192024-07-262024-08-162024-11-152025-01-172026-01-16
GlaxoSmithKline PLC's option chain is a display of a range of information that helps investors for ways to trade options on GlaxoSmithKline. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for GlaxoSmithKline. It also shows strike prices and maturity days for a GlaxoSmithKline PLC against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Delta | Gamma | Open Int | Expiration | Current Spread | Last Price | |||
Call | 2024-07-19 CALL at $25.0 | 0.9272 | 0.0084 | 12 | 2024-07-19 | 14.5 - 18.8 | 19.4 | In |
Call | 2024-07-19 CALL at $30.0 | 0.8961 | 0.0155 | 0 | 2024-07-19 | 9.6 - 13.8 | 0.0 | In |
Call | 2024-07-19 CALL at $35.0 | 0.8243 | 0.0326 | 0 | 2024-07-19 | 5.4 - 8.4 | 0.0 | In |
Call | 2024-07-19 CALL at $36.0 | 0.8605 | 0.041 | 1 | 2024-07-19 | 3.5 - 7.5 | 5.64 | In |
Call | 2024-07-19 CALL at $37.0 | 0.9633 | 0.0306 | 0 | 2024-07-19 | 3.6 - 4.7 | 0.0 | In |
Call | 2024-07-19 CALL at $38.0 | 0.8857 | 0.0687 | 14 | 2024-07-19 | 2.85 - 3.7 | 3.7 | In |
Call | 2024-07-19 CALL at $39.0 | 0.7549 | 0.0934 | 57 | 2024-07-19 | 2.05 - 3.2 | 2.8 | In |
Call | 2024-07-19 CALL at $40.0 | 0.7005 | 0.1509 | 34 | 2024-07-19 | 1.25 - 1.9 | 1.9 | In |
Call | 2024-07-19 CALL at $41.0 | 0.5319 | 0.1457 | 549 | 2024-07-19 | 1.05 - 1.2 | 1.15 | In |
Call | 2024-07-19 CALL at $42.0 | 0.3865 | 0.1428 | 417 | 2024-07-19 | 0.6 - 0.7 | 0.7 | Out |
Call | 2024-07-19 CALL at $43.0 | 0.2431 | 0.1247 | 718 | 2024-07-19 | 0.3 - 0.4 | 0.45 | Out |
Call | 2024-07-19 CALL at $44.0 | 0.1559 | 0.0902 | 305 | 2024-07-19 | 0.15 - 0.25 | 0.21 | Out |
Call | 2024-07-19 CALL at $45.0 | 0.0851 | 0.0592 | 270 | 2024-07-19 | 0.05 - 0.1 | 0.1 | Out |
Put | 2024-07-19 PUT at $36.0 | -0.0383 | 0.0263 | 44 | 2024-07-19 | 0.0 - 0.1 | 0.05 | Out |
Put | 2024-07-19 PUT at $37.0 | -0.0716 | 0.0448 | 3 | 2024-07-19 | 0.05 - 0.15 | 0.12 | Out |
Put | 2024-07-19 PUT at $38.0 | -0.1297 | 0.0708 | 12 | 2024-07-19 | 0.1 - 0.2 | 0.2 | Out |
Put | 2024-07-19 PUT at $39.0 | -0.1806 | 0.1061 | 4 | 2024-07-19 | 0.2 - 0.3 | 0.15 | Out |
Put | 2024-07-19 PUT at $40.0 | -0.2995 | 0.1511 | 199 | 2024-07-19 | 0.4 - 0.5 | 0.45 | Out |
Put | 2024-07-19 PUT at $41.0 | -0.4661 | 0.1839 | 603 | 2024-07-19 | 0.75 - 0.9 | 0.8 | Out |
Put | 2024-07-19 PUT at $42.0 | -0.6481 | 0.1734 | 193 | 2024-07-19 | 1.3 - 1.45 | 1.35 | In |
Put | 2024-07-19 PUT at $43.0 | -0.8777 | 0.1265 | 298 | 2024-07-19 | 1.7 - 2.3 | 1.45 | In |
Put | 2024-07-19 PUT at $44.0 | -0.8085 | 0.0888 | 325 | 2024-07-19 | 2.65 - 3.2 | 2.8 | In |
Put | 2024-07-19 PUT at $45.0 | -0.7821 | 0.0664 | 817 | 2024-07-19 | 3.4 - 5.4 | 3.3 | In |
Put | 2024-07-19 PUT at $46.0 | -0.8015 | 0.0551 | 6 | 2024-07-19 | 4.3 - 6.5 | 2.3 | In |
Put | 2024-07-19 PUT at $47.0 | -0.8921 | 0.0433 | 5 | 2024-07-19 | 5.1 - 7.1 | 2.55 | In |
Put | 2024-07-19 PUT at $48.0 | -0.8281 | 0.0411 | 0 | 2024-07-19 | 6.0 - 8.8 | 0.0 | In |
Put | 2024-07-19 PUT at $49.0 | -0.847 | 0.0551 | 0 | 2024-07-19 | 6.9 - 9.8 | 0.0 | In |
Put | 2024-07-19 PUT at $50.0 | -0.8654 | 0.032 | 0 | 2024-07-19 | 7.8 - 10.8 | 0.0 | In |
Put | 2024-07-19 PUT at $55.0 | -0.9068 | 0.0198 | 0 | 2024-07-19 | 13.1 - 15.3 | 0.0 | In |
Put | 2024-07-19 PUT at $60.0 | -0.8816 | 0.0169 | 0 | 2024-07-19 | 18.1 - 20.8 | 0.0 | In |
Put | 2024-07-19 PUT at $65.0 | -0.8914 | 0.0138 | 0 | 2024-07-19 | 23.1 - 25.8 | 0.0 | In |
GlaxoSmithKline PLC Market Cap Over Time
Market Cap |
| Timeline |
GlaxoSmithKline Total Stockholder Equity
Total Stockholder Equity |
|
GlaxoSmithKline PLC Corporate Directors
| Lynn Elsenhans | Independent Non-Executive Director | Profile | |
| Harry Dietz | Non-Executive Independent Director, Scientific and Medical Expert | Profile | |
| Charles Bancroft | Non-Executive Independent Director | Profile | |
| Vivienne Cox | Independent Non-Executive Director and Workforce Engagement Director | Profile |
Additional Information and Resources on Investing in GlaxoSmithKline Stock
When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.30) | Dividend Share 0.59 | Earnings Share 2.77 | Revenue Per Share 15.15 | Quarterly Revenue Growth 0.059 |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.